Find a list of our publications on PubMed

2022

  • Xu X, Wang K, Vera O, Verma A, Jasani N, Bok I, Elemento O, Du D, Yu X, Karreth FA. Gain of chromosome 1q perturbs a competitive endogenous RNA network to promote melanoma metastasisCancer Res. 2022 Aug 31:can.22.0283.

  • Mecozzi N, Nenci A, Vera O, Bok I, Falzone A, DeNicola GM, Karreth FA. Genetic tools for the stable overexpression of circular RNAs. RNA Biol. 2022 Jan;19(1):353-363.

  • Li J, Smalley I, Chen Z, Wu JY, Phadke MS, Teer JK, Nguyen T, Karreth FA, Koomen JM, Sarnaik AA, Zager JS, Khushalani NI, Tarhini AA, Sondak VK, Rodriguez PC, Messina JL, Chen YA, Smalley KSM. Single cell characterization of the cellular landscape of acral melanoma identifies novel targets for immunotherapyClin Cancer Res. 2022 Mar 4:clincanres.3145.2021. doi: 10.1158/1078-0432.CCR-21-3145.

  • Nakamura K, Reid BM, Chen A, Chen Z, Goode EL, Permuth JB, Teer JK, Tyrer J, Yu X, Kanetsky PA, Pharoah PD, Gayther SA, Sellers TA, Lawrenson K, Karreth FA. Functional analysis of the 1p34.3 risk locus implicates GNL2 in high-grade serous ovarian cancerAm J Hum Genet. 2022 Jan 6;109(1):116-135.

2021

  • Bok I, Angarita A, Douglass, SM, Weeraratna AT, Karreth FA. A series of BRAF-and NRAS-driven murine melanoma cell lines with inducible gene modulation capabilitiesJID Innovations. 2021 Nov, 100076

  • Mecozzi N, Vera O, Karreth FA. Squaring the circle: circRNAs in melanomaOncogene. 2021 Sep;40(37):5559-5566.

  • Bok I, Karreth FA. Strategies to Study the Functions of Pseudogenes in Mouse Models of Cancer. Methods Mol Biol. 2021;2324:287-304.

  • Xu X, Karreth FA. Pseudogenes as Competitive Endogenous RNAs: Testing miRNA DependencyMethods Mol Biol. 2021;2324:131-147.

  • Karreth FA, Ala U, Provero P, Pandolfi PP. Pseudogenes as Competitive Endogenous RNAs: Target Prediction and ValidationMethods Mol Biol. 2021;2324:115-129.

  • Smalley KSM, Teer JK, Chen YA, Wu JY, Yao J, Koomen JM, Chen WS, Rodriguez-Waitkus P, Karreth FA, Messina JL. A Mutational Survey of Acral NeviJAMA Dermatol. 2021 May 12:e210793.

  • Vera O, Bok I, Jasani N, Nakamura K, Xu X, Mecozzi N, Angarita A, Wang K, Tsai KY, Karreth FA. Vera O, Bok I, Jasani N, Nakamura K, Xu X, Mecozzi N, Angarita A, Wang K, Tsai KY, Karreth FA. A MAPK/miR-29 Axis Suppresses Melanoma by Targeting MAFG and MYBL2Cancers (Basel). 2021 Mar 19;13(6):1408.

  • Patton EE, Mueller KL, Adams DJ, Anandasabapathy N, Aplin AE, Bertolotto C, Bosenberg M, Ceol CJ, Chi P, Herlyn M, Holmen SL, Karreth FA, Kaufman CK, Khan S, Kobold S, Leucci E, Levy C, Lombard DB, Lund AW, Marie KL, Marine JC, Marais R, McMahon M, Robles-Espinoza CD, Ronai ZA, Samuels Y, Soengas MS, Villanueva J, Weeraratna AT, White RM, Yeh I, Zhu J, Zon LI, Hurlbert MS, Merlino G. Melanoma models for the next generation of therapiesCancer Cell. 2021 Feb 4:S1535-6108(21)00055-6.

2020

  • Vera O, Jasani N, Karreth FA. Long Non-coding RNAs in Melanoma Development and Biology. Proceedings of the Singapore National Academy of Science. 2020; Vol. 14, No. 02, pp. 146-166.

  • Kang YP, Falzone A, Liu M, González-Sánchez P, Choi BH, Coloff JL, Saller JJ, Karreth FA, DeNicola GM. PHGDH supports liver ceramide synthesis and sustains lipid homeostasisCancer Metab. 2020 Jun 15;8:6.

  • Bok I, Vera O, Xu X, Jasani N, Nakamura K, Reff J, Nenci A, Gonzalez JG, Karreth FA. A versatile ES cell-based melanoma mouse modeling platformCancer Res. 2020 Feb 15;80(4):912-921.

  • Chen YA, Teer JK, Eroglu Z, Wu JY, Koomen JM, Karreth FA, Messina JL, Smalley KSM. Translational pathology, genomics and the development of systemic therapies for acral melanomaSemin Cancer Biol. 2020 Apr;61:149-157.

 

2019

  • Karreth FA. A Roadmap for the Computational Prediction and Experimental Validation of Competitive Endogenous RNAs. Methods Mol Biol. 2019;1970:237-250.

  • Eroglu Z, Holmen SL, Chen Q, Khushalani NI, Amaravadi R, Thomas R, Ahmed KA, Tawbi H, Chandra S, Markowitz J, Smalley I, Liu JKC, Chen YA, Najjar YG, Karreth FA, Abate-Daga D, Glitza IC, Sosman JA, Sondak VK, Bosenberg M, Herlyn M, Atkins MB, Kluger H, Margolin K, Forsyth PA, Davies MA, Smalley KSM. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunitiesPigment Cell Melanoma Res. 2019 May;32(3):458-469. 

 

2018

  • Liu H, Murphy CJ, Karreth FA, Emdal KB, White FM, Elemento O, Toker A, Wulf GM, Cantley LC. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast CancerCancer Discov. 2018 Mar;8(3):354-3692017

  • Vera O, Rodriguez-Antolin C, de Castro J, Karreth FA, Sellers TA, de Caceres II. An epigenomic approach to identify differential overlapping and cis-acting lncRNAs in cisplatin-resistant cancer cellsEpigenetics. 2018 Feb 13:1-30.

 

2017

  • Permuth JB, Chen DT, Yoder SJ, Li J, Smith AT, Choi JW, Kim J, Balagurunathan Y, Jiang K, Coppola D, Centeno BA, Klapman J, Hodul P, Karreth FA, Trevino JG, Merchant N, Magliocco A, Malafa MP, Gillies R. Linc-ing Circulating Long Non-coding RNAs to the Diagnosis and Malignant Prediction of Intraductal Papillary Mucinous Neoplasms of the Pancreas. Sci Rep. 2017 Sep 5;7(1):10484.

  • Yoon SO, Shin S, Karreth FA, Buel GR, Jedrychowski MP, Plas DR, Dedhar S, Gygi SP, Roux PP, Dephoure N, Blenis J. Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition. Mol Cell. 2017 Aug 3;67(3):512-527.

 

2015

  • DeNicola GM+, Karreth FA+#, Adams DJ, Wong CC#The utility of transposon mutagenesis for cancer studies in the era of genome editing. Genome Biol. 2015 Oct 19;16:229. + equal contribution, # co-corresponding author

  • Perna D+, Karreth FA+, Rust AG, Perez-Mancera PA, Rashid M, Iorio F, Alifrangis C, Arends MJ, Bosenberg M, Bollag G, Tuveson DA, Adams DJ. BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model. PNAS. 2015 Feb 10;112(6):E536-45. + equal contribution

  • Karreth FA, Reschke M, Ruocco A, Ng C, Chapuy B, Leopold V, Sjoberg M, Keane TM, Verma A, Ala U, Tay Y, Wu D, Seitzer N, Del Castillo Velasco-Herrera M, Bothmer A, Fung J, Langellotto F, Rodig SJ, Elemento O, Shipp MA, Adams DJ, Chiarle R, Pandolfi PP. The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo. Cell. 2015 Apr 9;161(2):319-32.

 

2014

  • Tay Y, Tan SM, Karreth FA, Lieberman J, Pandolfi PP. Characterization of Dual PTEN and p53-Targeting MicroRNAs Identifies MicroRNA-638/Dnm2 as a Two-Hit Oncogenic Locus. Cell Rep. 2014 Aug 7;8(3):714-22.
  • Sadow PM, Priolo C, Nanni SKarreth FA, Duquette M, Martinelli R, Husain A, Clohessy J, Kutzner H, Mentzel T, Carman CV, Farsetti A, Henske EP, Palescandolo E, Macconaill LE, Chung S, Fadda G, Lombardi CP, De Angelis AM, Durante O, Parker JA, Pontecorvi A, Dvorak HF, Fletcher C, Pandolfi PP, Lawler J, Nucera C. Role of BRAFV600E in the First Preclinical Model of Multifocal Infiltrating Myopericytoma Development and Microenvironment. J Natl Cancer Inst. 2014 Jul 25;106(8).

  • Karreth FA, Tay Y, Pandolfi P. Target competition: transcription factors enter the limelight. Genome Biol. 2014 Apr 28;15(4):114.

  • Karreth FA, Ala U, Provero P, Pandolfi PP. Pseudogenes as competitive endogenous RNAs: target prediction and validation. Methods Mol Biol. 2014;1167:199-212.

  • Tay Y, Karreth FA, Pandolfi PP. Aberrant ceRNA activity drives lung cancer. Cell Res. 2014 Mar;24(3):259-60.

 

2013

  • Karreth FA, Pandolfi PP. ceRNA Cross-Talk in Cancer: When ce-bling Rivalries Go AwryCancer Discovery. 2013 Oct;3(10):1113-21.

  • Ala U+, Karreth FA+, Bosia C, Pagnani A, Taulli R, Leopold V, Tay Y, Provero P, Zecchina R, Pandolfi PP. Integrated transcriptional and competitive endogenous RNA networks are cross-regulated in permissive molecular environmentsPNAS. 2013 Apr 30;110(18):7154-9. + equal contribution

 

2012

  • Gopinathan A, DeNicola GM, Karreth FA, Reinheckel T, Tuveson DA. Cathepsin-B promotes the progression of pancreatic ductal adenocarcinoma in miceGut. 2012 Jun;61(6):877-84.

 

2011

  • Karreth FA, Tay Y, Perna D, Ala U, Tan SM, Rust AG, DeNicola GM, Webster KA, Weiss D, Perez-Mancera PA, Krauthammer M, Halaban R, Provero P, Adams DJ, Tuveson DA, Pandolfi PP. In vivo identification of tumor suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell. 2011 Oct 14;147(2):382-95.

  • Tay Y, Kats L, Salmena L, Weiss D, Tan SM, Ala U, Karreth F, Poliseno L, Provero P, Di Cunto F, Lieberman J, Rigoutsos I, Pandolfi PP. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAsCell. 2011 Oct 14;147(2):344-57.

  • Karreth FA, Frese KK, DeNicola GM, Baccarini M, Tuveson DA. C-Raf is required for the initiation of lung cancer by K-RasG12. Cancer Discovery. July 2011 1:128-136.

  • DeNicola GM, Karreth FA, Wei C, Frese K, Mangal D, Gopinathan A, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, Tuveson DA. Ras oncogene-induced ROS detoxification promotes tumorigenesisNature. 2011 Jul 6;475(7354):106-9.

 

2010

  • Skoulidis F, Cassidy LD, Pisupati V, Jonasson JG, Bjarnason H, Eyfjord JE, Karreth FA, Lim M, Barber LM, Clatworthy SA, Davies SE, Olive KP, Tuveson DA, Venkitaraman AR. Germline Brca2 Heterozygosity Promotes KrasG12D-Driven Carcinogenesis in a Murine Model of Familial Pancreatic Cancer. Cancer Cell. 2010 Nov 16;18(5):499-509.

  • Meixner A, Karreth F, Kenner L, Penninger JM, Wagner EF. Jun and JunD-dependent functions in cell proliferation and stress responseCell Death Differ. 2010 Mar 19.

 

2002-2009

  • Karreth FA, DeNicola GM, Winter SP, Tuveson DA. C-Raf inhibits MAPK activation and transformation by B-RafV600E. Mol Cell. 2009 Nov 13;36(3):477-86.

  • Karreth FA, Tuveson DA. Modelling oncogenic Ras/Raf signaling in the mouse. Curr Opin Genet Dev. 2009;19(1):4-11.

  • King AJ, Patrick DR, Batorsky RS, Ho ML, Do HT, Zhang SY, Kumar R, Rusnak DW, Takle AK, Wilson DM, Hugger E, Wang L, Karreth F, Lougheed JC, Lee J, Chau D, Stout TJ, May EW, Rominger CM, Schaber MD, Luo L, Lakdawala AS, Adams JL, Contractor RG, Smalley KS, Herlyn M, Morrissey MM, Tuveson DA, Huang PS. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res. 2006 Dec 1;66(23):11100-5.

  • Karreth F and Tuveson DA. Twist induces an epithelial-mesenchymal transition to facilitate tumor metastasis. Cancer Biol Ther. 2004 Nov;3(11):1058-9.

  • Karreth F, Hoebertz A, Eferl R, Wagner EF. The AP-1 transcription factor Fra-2 is required for efficient cartilage developmentDevelopment, 2004 131: 5717-5725.

  • Eferl R, Hoebertz A, Schilling AF, Rath M, Karreth F, Kenner L, Amling M, Wagner EF. The Fos-related antigen Fra-1 is an activator of bone matrix formationEMBO J, 2004 Jul 21;23(14):2789-99

  • Meixner A, Karreth F, Kenner L, Wagner EF. JunD regulates lymphocyte proliferation and T helper cell cytokine expressionEMBO J. 2004 Mar 24;23(6):1325-35.

  • Gruber R, Karreth F, Kandler B, Fuerst G, Rot A, Fischer MB, Watzek G. Platelet-released supernatants increase migration and proliferation, and decrease osteogenic differentiation of bone marrow-derived mesenchymal progenitor cells under in vitro conditionsPlatelets. 2004 Feb;15(1):29-35.

  • Kenner L, Hoebertz A, Beil T, Keon N, Karreth F, Eferl R, Scheuch H, Srzemska A, Amling M, Schorpp-Kistner M, Angel P, Wagner EF. Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defectsJ Cell Biol. 2004 Feb 16;164(4):613-23.

  • Gruber R, Karreth F, Frommlet F, Fischer MB, Watzek G. Platelets are mitogenic for periosteum-derived cellsJ Orthop Res. 2003 Sep;21(5):941-8.

  • Gruber R, Schofnagl M, Karreth F, Fischer MB, Watzek G. The stable analog carbocyclic TXA2 but not platelet-released TXA2 induces osteoclast-like cell formationProstaglandins Leukot Essent Fatty Acids. 2003 Apr;68(4):267-72.

  • Gruber R, Karreth F, Fischer MB, Watzek G. Platelet-released supernatants stimulate formation of osteoclast-like cells through a prostaglandin/RANKL-dependent mechanismBone. 2002 May;30(5):726-32.